Introduction

GSK1322322 (N-((R)-2-(cyclopentylmethyl)-3-(2-(5-fluoro-6-((S)-hexahydropyrazino
oxazin-8(1H)-yl)-2-methylpyrimidin-4-yl)hydrazinyl)-3-oxopropyl)-N-hydroxy-formamide) is a novel, potent, and reversible inhibitor of bacterial peptide deformylase (PDF) that is in development at GlaxoSmithKline (GSK) for potential i.v. and oral treatment of hospitalized community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. PDF is essential for bacterial protein maturation and a likely new target for antibiotic action (Giglione and Meinnel, 2001 ). Because of this novel mechanism, GSK1322322 has demonstrated activity against pathogens resistant to existing antibiotics (b-lactams, macrolides, and quinolones).
Plasma, urine, and feces are typically collected to understand the metabolism and elimination of a drug; however, bile collection is not common. Bile sampling can often provide crucial information about the disposition of the compound. Several methods of collecting human bile have been attempted, with varied levels of success (Balani et al., 1997; Wang et al., 2006) . Unfortunately, these methods tend to be invasive or difficult to use. The Entero-Test capsule is a simple apparatus that was first developed more than 30 years ago for the sampling of duodenal bile acids (Vonk et al., 1986) . Recently, GSK pioneered its use in metabolism studies. The device has proven useful in sampling bile from both dogs and human subjects in nonradiolabeled metabolism studies (Guiney et al., 2011; Bloomer et al., 2012) , but it has never been tested in a conventional human radiolabel study where its application could be fully evaluated.
In this study, we investigated the absorption, bioavailability, metabolism, and excretion of [ base, specific activity of 124.4 mCi/mg, radiochemical purity of 99.5%) was prepared by GSK (Stevenage, UK). As illustrated in Fig. 1 , a single Chemicals and solvents of reagent or high-performance liquid chromatography (HPLC) grade were purchased from standard commercial sources. Scintillation cocktails Ultima Gold, Permafluor, Carbosorb CO 2 absorbent, and SafeScint 1:1 were obtained from PerkinElmer Life and Analytical Sciences (Waltham, MA) or LabLogic (Sheffield, UK). HPLC columns were purchased from Phenomenex (Torrance, CA). Sucrose (IAEA-C6) (certificated value = 1.506Â modern) was purchased from the International Atomic Energy Agency (Vienna, Austria) and used as the source of graphite (6.5 mg of sugar for each graphite produced) in AMS instrument normalization and process control. Synthetic graphite 200 Mesh (99.9999%), from Alfa Aesar (Heysham, UK), was used as the AMS instrument background determination standard.
Dosing of Human Subjects
This open-label, single dose (i.v. and oral solution), crossover study to investigate the disposition of GSK1322322 in healthy humans was conducted at DaVita Clinical Research (Minneapolis, MN) under clinical study PDF112167 (registered as NCT01663389). Five healthy adult white male volunteers between the ages of 30 and 55 years (body weight #75 kg and body mass index between 21 and 24 kg/m 2 ) were enrolled. Subjects fasted at least 10 hours before dosing for each dosing period. In period 1, each subject received a single i.v. dose of 1000 mg (45.5 mCi) of [ 14 C]GSK1322322 as a 100 mg/ml solution in sterile water (10 ml) via an i.v. infusion over 60 minutes. Period 2 commenced after the total radioactivity in both urine and feces was ,1% of the administered dose in two consecutive 24-hour collections. In period 2, each subject received a single oral dose of 1200 mg (54.5 mCi) of [ 14 C]GSK1322322 as a 100 mg/ml solution in sterile water (12 ml). The amount of [ 14 C]GSK1322322 ingested by each subject was determined by analyzing the dosing solution in each dosing bottle before and after dose administration.
Collection of Samples
For each subject, blood samples (8 ml) were drawn at predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 , and 168 hours postdose for dmd.aspetjournals.org pharmacokinetic (PK) analysis of GSK1322322, M6, and M9. In addition, 10 ml blood samples were collected at both periods at predose, 0.5 hour (period 2 only), 1 hour (period 1 only), and 2, 4, 8, 24, and 48 hours for metabolic profiling. Plasma was harvested by centrifugation. Urine (10 ml) was aliquoted at predose, 0-6 hours, 6-12 hours, and 12-24 hours during day 1 and in 24-hour intervals up to 216 hours postdose for period 1 and 192 hours for period 2.
Bile was collected noninvasively using the Entero-Test capsule. The capsule was inserted at 3.5 hours predose and removed 2 hours after i.v. infusion in period 1. In period 2, the capsule was inserted 2 hours after oral dosing and removed 6.5 hours postdose. Food cues were used to stimulate emptying of the gallbladder at 0.5 hour postinfusion start or 5.5 hours after the oral dose. The strings were gently removed by pulling the line upward and out while the subject's head was tilted backward.
Feces were collected at predose and then over 24-hour collection intervals up to 216 hours postdose in period 1 and 192 hours in period 2. The steel weight from the Entero-Test was removed from the feces. The fecal samples were then mixed with water (five times the sample weight) and homogenized using a probe-type homogenizer.
Analysis of Radioactivity
Blood and Feces. Duplicate weighed aliquots of each blood and fecal homogenate sample (0.2 g) were combusted and analyzed for radioactivity. The combustion was performed in a Packard model 307 sample oxidizer (Packard Instrument Co., Meriden, CT). The resulting CO 2 was trapped in a Permafluor and Carbo-Sorb mixture, and the radioactivity was measured by liquid scintillation counting (LSC).
Plasma and Urine. Duplicate weighed aliquots (0.2 g) of each plasma and urine sample were transferred to scintillation vials and analyzed directly for radioactivity. Ultima Gold XR scintillation cocktail (5 ml) was added to each vial and counted in a scintillation counter for 5 minutes or 100,000 counts. The total plasma and urine radioactivity concentrations were calculated by converting the LSC data in disintegrations per minute per milliliter to concentrations (mass equivalents per gram) using the specific activity of [ 14 C]GSK1322322 (0.044 mCi/mg). Plasma by AMS. The AMS analysis procedure was previously reported (Young et al., 2008) . Plasma samples, especially those collected at later time points that had levels of radioactivity too low to be determined by LSC, were subject to AMS analysis. Aliquots of plasma (0.01 ml) from these samples were supplemented with an aliquot of control human plasma (0.05 ml) to yield the optimum carbon content equivalent to about 2.6 mg after preparation to graphite. The resulting graphite/cobalt mix was packed into an aluminum cathode, and each sample was analyzed using a 250-kV single-stage accelerator mass spectrometer instrument (National Electrostatics Corp., Middleton, WI). A generic value of 4.14%, based on GSK historical data, for the carbon content of human plasma generated using a Costech Elemental Combustion System (Model 4010; Valencia, CA) CHNS-O Analyzer (Pelican Scientific Ltd., Chester, UK), was used for all samples analyzed. The AMS data, expressed as percentage of modern carbon, were used to calculate the disintegrations per minute per milliliter of each sample, where 100% modern carbon equals 0.01356 disintegrations per minute per milligram of carbon.
Quantitation of GSK1322322, M6, and M9 in Plasma
The PK plasma samples were analyzed for the presence of GSK1322322 using a validated liquid chromatography-tandem mass spectrometry (LC-MS/ MS) analytical method similarly described (Naderer et al., 2013A) . The PK plasma samples were also analyzed to determine the concentration of M6 and M9. GSK2298310 (M6) and GSK2298314 (M9) were extracted from human plasma by protein precipitation using acetonitrile containing [ 13 C 15 N 2 ]GSK1322322 as an internal standard. Extracts were analyzed by ultra-HPLC-MS/MS using a TurboIonspray interface with positive ion multiple reaction monitoring. The assay range was 20 to 20,000 ng/ml and 5 to 5000 ng/ml for M6 and M9, respectively. Both metabolites were stable in plasma for at least 8 hours at ambient temperature and 76 days in storage at 280°C.
Pharmacokinetic Analysis of Radioactivity, GSK1322322, M6, and M9
Blood and plasma total radioactivity and plasma GSK1322322 PK parameters, including area under the curve (AUC 0-t , and AUC 0-' ),C max , time of C max observed (t max ), terminal half-life (t 1/2 ), systemic clearance (i.v. administration only), and volume of distribution at steady state (i.v. administration only) were determined for each subject by noncompartmental analysis using WinNonlin (version 6.2.1; Pharsight, Mountain View, CA). Plasma PK parameters for M6 and M9, including AUC 0-t , AUC 0-' , C max , t max , and t 1/2 , were also determined by noncompartmental analysis using Phoenix WinNonlin. The ratio of plasma GSK1322322 to plasma total radioactivity was calculated to assess the relative amount of radioactivity present as parent compound versus metabolites. The ratio of blood to plasma total radioactivity concentrations at each PK sampling time point was calculated to assess GSK1322322 partitioning into red blood cells. Concentration units for radioactivity were expressed as microgram equivalents of GSK1322322 per milliliter.
Preparation of Samples for Radio Profiling
Plasma. Equal-volume aliquots (0.05 ml) from each PK sampling time point, up to and including 24 hours, were combined across subjects to create 22 discrete i.v. and oral-dose pooled plasma samples. These samples were then pooled according to the method described by Hop et al. (1998) to provide two pools of plasma. Plasma samples at 48 hours postdose were not examined because of the very low levels of radioactivity present. Each pooled plasma sample (50 ml) was diluted 20-fold with water and dimethylformamide (1:18:1, v/v/v), which contained authentic nonradiolabeled reference standards of GSK1322322, M6, and M9 each at a concentration of 1666 mg/ml (83 mg/ml after dilution). The diluted pooled plasma samples were analyzed by HPLC with radiometric detection by off-line analysis by AMS.
Urine. The urine samples from each subject were pooled to produce a single representative sample for the subject on the basis of the total sample weight collected from each interval. Samples with less than 2% of the administered dose were not pooled. The pooled urine samples were centrifuged at 3000 g av at 4°C for 5 minutes to remove any particulates before analysis by radio-HPLC. Triplicate aliquots of each pooled urine sample were analyzed before and after centrifugation to determine whether any notable loss of radioactivity occurred on centrifugation.
Feces. Fecal samples were pooled to generate a representative sample for each subject. The pooled samples were extracted twice with a mixture of methanol and water (1:4, v/v) followed by extraction with methanol. Each extraction involved the addition of 3 volumes of the solvent, followed by sonication for 0.5 minute, mixing at room temperature for 1 hour, and centrifugation (3000 g av at 4°C for 5 minutes). The supernatants were combined, and triplicate aliquots of the combined supernatant were analyzed by LSC to determine the radioactivity content. Each extract was then concentrated on wet ice under a stream of nitrogen gas. The concentrated sample was mixed at 10°C for 30 minutes and centrifuged (3000 g av at 4°C for 5 minutes). Triplicate aliquots of the concentrate supernatant were analyzed by LSC to determine the total radioactivity before radio-HPLC analysis.
Bile. Radioactive material was extracted from each bile string with the addition of 3 ml of methanol and water (1:4, v/v). The string was gently agitated by inversion of the container. The extract was decanted into another container. The string was then rinsed twice with 3 ml of methanol, and all washes were combined with the initial extract to produce 10 individual bile string extracts (five from each period). Equal-volume aliquots (1 ml) from the individual bile string extracts were combined to produce two route specific pools. An aliquot (1 ml) was removed from each pool for analysis by LSC to determine the radioactivity content. The two pooled bile string extracts were then diluted 20-and 100-fold, respectively, with a mixture of water and dimethylformamide containing authentic nonradiolabeled reference standards of GSK1322322, M6, and M9, each at concentrations of 1666 mg/ml (83 mg/ml after dilution). The diluted bile samples were analyzed by HPLC with radiometric detection by off-line analysis by AMS.
In Vitro Incubation of [ 14 C]GSK1322322 with Human Fecal Contents Fecal Incubation. The human fecal homogenate incubation procedure was modified from an established method by Fouda et al. (1997) . A fresh feces sample pooled from three anonymous healthy volunteers was commercially obtained (Bioreclamation Co., Westbury, NY). On receipt, the feces sample was homogenized with 0.1 M sodium phosphate buffer, pH 7.4 (previously gassed with nitrogen), under nitrogen to minimize atmospheric contact. Then the sample was transferred to an anaerobic chamber purged with nitrogen. Approximately 10 ml of the feces homogenate was removed into a culture bottle containing 20 ml of media (0.5% glucose, 0.5% yeast extract, and 0.5% peptone in 0.1 M sodium phosphate buffer, pH 7.4). The culture bottle was sealed with Teflon tape, removed from the anaerobic chamber, and placed in a 37°C water bath for approximately 1 hour. After the preincubation, the fecal content suspension was returned to the anaerobic chamber.
In the chamber, a 1-ml aliquot of incubation medium containing 52 mM [ 14 C]GSK1322322 was added to each of the culture tubes containing 1 ml of fecal homogenate suspension. The tubes were sealed with Teflon tape, removed from the anaerobic chamber, and incubated in a water bath (37°C) for 24 hours and protected from light. After completion of the incubation, reactions were stopped by the addition of 2 ml of methanol. Samples were vortex-mixed and centrifuged at approximately 3500 g av for 5 minutes. The resulting supernatant was analyzed by HPLC-MS n with offline radiodetection. Control incubations without GSK1322322 were conducted in parallel using a blank medium containing 25 ml of methanol. Control incubations without fecal homogenate were also conducted using the incubation medium containing the same amount of [ 14 C]GSK1322322. Bacterial Viability Check. To confirm fecal bacterial activity, incubations were performed by incubating 1 ml of fecal homogenate suspension with 1 ml of 50 mg/ml methylene-blue in media for 24 hours at 37°C (LeBoffe and Pierce, 1996) . Bacterial activities in the incubations were verified at 24 hours by noting any color change in the samples (blue = no activity; absence of blue = activity).
Heat/Antibiotic Treatment. To verify further the bacterial activity in the feces, approximately half of the original human fecal homogenate suspensions were heat-treated by placing the suspension tubes in a boiling water bath for 15 minutes. The samples were then allowed to cool to room temperature when a mixture of antibiotics (2.44 ml of 50 mg/ml bacitracin in water, 0.976 ml of 125 mg/ml neomycin in water, and 0.976 ml of 125 mg/ml streptomycin in water) (Kinouchi et al., 1993) was added to the samples and mixed. Incubations with heat-and antibiotics-treated samples were conducted similarly as discussed already.
Radio-HPLC Analysis of Metabolites
Plasma and Bile. The Agilent 1100 LC system (South Queensferry, Scotland, UK) consisted of a binary pump, autosampler, ultraviolet detector (l 254 nm), and fraction collector. Aliquots (100 ml) of the diluted samples were injected onto a Phenomenex Synergi Polar-RP column (4.6 Â 250 mm, 4 mm, 80Å) (Torrance, CA) and eluted at 1 ml/min with solvents A (25 mM ammonium formate buffer, pH 3.78) and B (methanol). The following four-step gradient was used: 0-5 minutes, 5% solvent B in solvent A; 5-80 minutes, 5% to 85% B in A; 80-80.2 minutes, 85% to 100% B in A; and 80.2-85 minutes, 100% B. After elution of GSK1322322 and its metabolites, the gradient was switched back to 5% B in A, and the column was washed for 5 minutes before the next injection. Each sample was individually fractionated at a frequency of 0.25 minutes over a time range of 15-70 minutes by HPLC. The fractionates were collected directly into quartz glass tubes (York Glassware Services, York, UK) containing carbon carrier (40 ml of aqueous sodium benzoate solution [625 mM], a source of carbon for isotopic dilution equating to 2.1 mg; essentially containing no 14 C). Each HPLC fraction was evaporated to dryness in a centrifugal evaporator for 4 hours, and then carbon in the sample was converted to graphite and subsequently analyzed for radioactivity by AMS (Young et al., 2008) . HPLC column recoveries were determined for the individual plasma and bile extract-fractionated chromatograms using AMS through comparison of precolumn injectates with dmd.aspetjournals.org total radioactivity of all fractions. Chromatograms were reconstructed by importing the AMS data into Laura (LabLogic, Broomhill, Sheffield, UK).
Urine and Feces. Urine and fecal samples were analyzed using Agilent 1200 LC systems. Except for injection volume (200 ml), the system configuration and LC gradient were identical to above description. After injection, HPLC eluent was collected onto four 96-well scintillator-coated microtiter plates (PerkinElmer Life and Analytical Sciences) at 0.194 minute/well. The solvents in the microtitre plates were vacuum-centrifuged in the speedvac (Model 1450; ThermoFisherScientific, Waltham, MA) at ambient temperature. The dried plates were then sealed using TopSeal-A film (PerkinElmer Life and Analytical Sciences) and analyzed using a Trilux Microbeta (Model 1450; PerkinElmer Life and Analytical Sciences). Each well was counted for 15 minutes without background subtraction. The resulting Microbeta data were imported into the Laura software using the "LSC Import" function to reconstruct radio-HPLC chromatograms. Each radioactive peak was calculated as a percentage of the total counts detected and expressed as the percentage of the dose recovered in feces (corrected for the combustion and extraction recovery) and in urine (corrected for centrifugation efficiency). The lower limit of quantitation was defined as twice the background area integrated in each chromatogram.
Mass Spectroscopic Analysis of Metabolites
Metabolite structural characterization was performed by LC-MS n analysis on a LTQ Orbitrap XL or LTQ XL ion trap mass spectrometers, with an electrospray ion source operating in positive ion mode. The LC conditions were identical to those used for radio-profiling as described above using an Agilent 1260 LC system. Synthetic standards were used for comparison of chromatographic retention times as well as to provide characteristic MS n fragmentation patterns. All instruments used a CTC PAL autosampler for sample injection. Data were acquired and processed using Xcalibur software (version 2.1; ThermoFisherScientific) and Advanced Chemistry Development (version 12; Toronto, ON, Canada).
Results
Safety
After both the single i.v. and the oral administration of [ 14 C]GSK1322322, the most frequently reported adverse event (AE) was headache. Four subjects had headaches during period 1; two subjects had headaches, and one had other adverse effects (diarrhea, nausea, oropharyngeal pain, throat irritation, and pain in extremity) during period 2. No serious AEs were reported. No subject discontinued the study medication or was withdrawn prematurely from the study as a result of adverse events.
Elimination and Mass Balance of Radioactivity
Five healthy male volunteers received a single 1050 mg i.v. dose of [ 14 C]GSK1322322 (46.1 mCi) during period 1 and a separate single 1270 mg oral dose of [ 14 C]GSK1322322 (55.9 mCi) during period 2. Period 2 commenced after the total radioactivity levels in urine and feces were ,1% of the administered dose after two consecutive 24-hour collections. The means (i.e., ranges) of total recoveries of radioactivity from the i.v. and oral administrations were high at 96% (92%-98%) and 92% (66%-100%), respectively. The radioactive dose was eliminated in urine and feces at approximately equal proportions after both routes of administration (;45%-48% each) ( Table 1) . Urinary elimination of radioactivity was basically completed by 48 hours and fecal elimination by 6 days postdose.
Pharmacokinetics of Total Radioactivity, GSK1322322, and Metabolites
Mean concentration-time profiles for blood and plasma radioactivity and plasma GSK1322322, M6, and M9 are displayed in Fig. 2 . The profiles of the two routes of administration were similar. Radioactivity and GSK1322322 concentrations quickly peaked postdose (t max between 0.5 and 1 hour), followed by biexponential decline. A summary of blood and plasma total radioactivity and plasma GSK1322322, M6, and M9 PK parameters is presented in Table 2 . After i.v. administration, the mean blood radioactivity and plasma GSK1322322 clearance were similar at 24 liters/hour. Plasma radioactivity clearance was lower at 15 liters/hour. The mean volume of distribution at steady state ranged from 49 liters for radioactivity in blood to 53 liters for GSK1322322 in plasma and 61 liters for radioactivity in plasma. Blood radioactivity concentrations were 58%-85% and 64%-88% of plasma radioactivity concentrations at corresponding time points after i.v. and oral administration, respectively (data not shown). Consistently, the mean blood: plasma radioactivity AUC 0-' ratio (calculated based on data in Table 2 ) ranged from 0.63 to 0.75, indicating minimal association of GSK1322322 or its metabolites with blood cells. The plasma exposure to GSK1322322 accounted for 64%-67% of the total plasma exposure to radioactivity for both dose routes, suggesting that the unchanged drug predominated in circulation ( Fig. 2; Table 2 ). Plasma exposure levels of M9 and M6 were 22%-28% and 3%-4% of the total plasma radioactivity exposure, respectively. After i.v. or oral administration, the median t 1/2 of GSK1322322 was 4.2-5.0 hours. The median t 1/2 values for M6 and M9 were approximately 2.5 hours after dosing. After oral administration, b M37, which coelutes with parent was determined to be ,1% of GSK1322322 from mass spectrum response compared with synthetic standards in pooled human plasma; oral dose at 0.5 hour. 
Downloaded from
GSK1322322 was measurable in the first sampling occasion (0.25 hour) with a t max observed at 0.5 hour after the dose.
Metabolite Profiles in Plasma
HPLC radiochromatograms of pooled plasma are depicted in Fig. 3 . The relative amounts of GSK1322322 and metabolites in plasma after i.v. and oral administration of [ 14 C]GSK1322322 are shown in Table 3 . Unchanged GSK1322322 was the predominant circulating component, accounting for 77%-80% of total plasma radioactivity in the pooled i.v. and oral plasma samples. M9, a glucuronide of GSK1322322, accounted for 11% and 15% of total radioactivity after i.v. and oral administration, respectively; M6, a product of deformylation of M9, was a minor component (,2% of total radioactivity in either regimen).
Metabolite Profiles in Urine
A representative HPLC radiochromatogram of urine was depicted in Fig. 4 . The individual and mean quantifications of metabolites from the five subjects are shown in Table 4 . The metabolite profiles were similar across subjects and between i.v. and oral administration profiles, with unchanged GSK1322322 and its coeluting N-dehydroxylated metabolite (M37) being the major radio components, accounting for 32% of the administered dose (23%-46%). M9 accounted for approximately 5% (3%-7%) of the dose after i.v. and oral administration. M1-M4 (products of mono-oxygenation of GSK1322322), along with their N-dehydroxylated forms (M38-M41) and M32 (a product of oxidative deamination plus ketone formation), were all minor, each accounting for ,1% of the administered dose.
Metabolite Profiles in Feces
A representative HPLC radiochromatogram of fecal homogenate extracts is shown in Fig. 5 . The individual and mean percentages of GSK1322322 and metabolites excreted in feces are shown in Table 4 . The metabolite profiles were similar across subjects and between i.v. and oral administration profiles. Unchanged GSK1322322 and its coeluting reduced form (M37) were predominant radioactive components, accounting for approximately 10% (6%-14%) of the dose. Metabolites M1-M4 and their N-dehydroxylated analogs (M38-M41) were also notable, together accounting for 17% of the dose. M6, M9, and M18 (a product of deformylation plus N-dehydroxylation) were all minor, each accounting for ,5% of the dose.
Metabolite Profiles in Entero-Test Collected Bile
Representative HPLC radiochromatograms of pooled duodenal bile string extracts are depicted in Fig. 6 ; relative abundance of GSK1322322 and metabolites is shown in Table 5 . The glucuronide conjugate of parent (M9) predominated in bile after i.v. and oral administration, accounting for 40% and 53% of total biliary radioactivity, respectively. Assuming that the Entero-Test snapshot represented the full biliary excretion (% of dose in bile should be equivalent to the dose eliminated in feces as a result of almost complete absorption of GSK1322322), glucuronidation (M6 and M9 together) would account for 20% (42% of 48% of fecal dose) and 25% of dose (56% of 45% of fecal dose), respectively, after i.v. and oral administration. Unchanged GSK1322322 and coeluting M37 accounted for 30% of biliary radioactivity but were M6, GSK2998310; M9, GSK2998314; M37, GSK2733752; NA, not applicable. a M1-M4, M2, and M38-M41 were ,2% of dose. b M37 was determined to be 12.6% of GSK1322322 from mass spectrum response compared with synthetic standards in the urine of human subject 2, oral dose.
c M6 and M18 coeluted in all but one subject. d M37 was determined to be 56.3% of GSK1322322 in the feces of human subject 2, oral dose.
less abundant in the bile after the oral dose (9% of biliary radioactivity). M1-M4 and their N-dehydroxylated forms (M38-M41), M18, and M6 were minor components, each accounting for ,7% of the bile radioactivity for both dose routes.
In Vitro Human Fecal Microbial Metabolism
The HPLC radiochromatograms and MS spectra of the fecal extracts after incubation with [ 14 C]GSK1322322 are depicted in Fig. 7 . In the presence of viable gut microbes, as evidenced by methyleneblue assays, GSK1322322 readily degraded to M37, as indicated by LC/MS data of the coeluting reduced analog. However, in the absence of viable gut microbes, GSK1322322 was stable.
Identification of Metabolites
Several metabolites (M1-M4, M6, and M9) have previously been identified in preclinical studies by HPLC-MS n and nuclear magnetic resonance analysis (Supplemental Materials and Methods). In this study, the structures of these metabolites and a few others (e.g., M37) were confirmed or characterized by HPLC-MS n analysis. The MS n fragmentation of GSK1322322 was shown in Fig. 8 and was used as a reference in characterizing the metabolites. Summaries of HPLC retention times and MS n data of observed metabolites are depicted in Table 6 . When possible, relevant standards were also analyzed to assist in metabolite identification.
Metabolites M6 and M9. M6 was characterized as an N-deformation and O-glucuronidation metabolite of GSK1322322. The protonated pseudomolecular ion, along with the diagnostic fragment ion of m/z 452 (loss of 176 Da), supported this characterization. The fragmentation ions at m/z 283, 419, and 434 were consistent with the fragmentation of GSK1322322. M9 was characterized as an O-glucuronidation at the hydroxyl amine moiety. The pseudomolecular ion of M9 at m/z 656 was 176 Da higher than GSK1322322, indicating glucuronidation. The fragment ion at m/z 267 is consistent with the MS 2 fragmentation of GSK1322322. m/z 480 is the loss of 176, which is typical of glucuronide conjugates, m/z 462 and others matched with the MS n from initiative characterizations. The M6 and M9 were previously characterized by accurate MS n and nuclear magnetic resonance earlier from preclinical studies with definite structures (Supplemental Tables 1-4) .
Metabolites M1-M4. For metabolites M1-M3, the pseudomolecular ion at m/z 496 was 16 Da higher than that of GSK1322322, indicating mono-oxygenation. The fragment ions at m/z 223 and 283 were consistent with the fragmentation of GSK1322322 and, together with the fragment ion at m/z 435, indicated oxidation of the ethyl-cyclopentane moiety as shown in Fig. 1 . M4 was 14 Da higher than that of GSK1322322, indicating the metabolism pathway is ketone formation. Fragment ions indicate ketone formation on the ethyl-cyclopentane moiety as well (Fig. 1) . M1-M4 were initiatively characterized from previous preclinical studies (Supplemental Tables 1-4) .
Metabolite M37. A synthetic standard (GSK2733752) was available to confirm structural assignment of this metabolite. The pseudomolecular ion at m/z 464 was consistent with N-dehydroxylation. The MS 2 was 446, which was a loss of H 2 O from m/z 464 by accurate mass confirmation. The fragmentation ions at m/z 223, 268, 281, 347, 419, and 428 matched with the MS 3 spectrum of GSK2733752. The chromatographic retention time of M37 matches with the standard, too.
Other Minor Metabolites. Several other minor metabolites were characterized by HPLC/MS n . However, their structural assignments were not described further here as they were present in minute quantities (M18, M32, and M38-M41).
Discussion
This article describes the results of an excretion and mass balance study in healthy human subjects that used Entero-Test as a novel method for parent and metabolite characterization in bile. Single doses of GSK1322322, given either i.v. (1000 mg) or orally (1200 mg), were well tolerated in healthy men without any notable adverse events. After i.v. administration, GSK1322322 had a volume of distribution approximating total body water (;42 liters for a 70 kg person), indicating that the drug may be distributing into all body water but not extensively into tissues. After the oral dose, GSK1322322 was quickly absorbed, as evidenced by its short t max (0.5 hour). Dose-normalized AUC 0-' from the oral dose was nearly identical to that after i.v. administration, suggesting close to complete absorption and bioavailability (97%) of the molecule. Systemic exposure (C max of 22 mg/ml and AUC 0-' of 49 mg×h/ml) after 1200 mg of oral solution was similar but higher than that in a previous study (C max of 19 mg/ml and dmd.aspetjournals.org AUC 0-' of 40 mg×h/ml) after oral administration of 1500 mg of a powder-in-bottle formulation, confirming that oral solution had better bioavailability than other oral formulations (Naderer et al., 2013A) . The terminal elimination half-life of GSK1322322 (5 hours) after oral administration was also similar to a previous observation (5.3-6.8 hours after single dose) (Naderer et al., 2013A) . Clearance and volume of distribution at steady state after a 1000 mg i.v. dose were in agreement with previous observations (Naderer et al., 2013C) M6, GSK2998310; M9, GSK2998314; M37, GSK2733752. a Liquid chromatography-tandem mass spectrometry work was completed on the bile extracts (pooled across subjects per period) to identify the metabolites radioprofiled using accelerator mass spectrometry.
b M37 was determined to be 4.3% of GSK1322322 from mass spectrum response compared with synthetic standards in pooled human bile, oral dose. .5 mCi) and 0-6.5 hours after oral administration (1200 mg, 54.5 mCi). Bile samples from each of the five human subjects per dose were subsequently pooled together and analyzed by solvent extraction, followed by LC/MS analysis.
Pharmacokinetic comparison of total plasma radioactivity with GSK1322322 indicated that GSK1322322 was the predominant component in circulation after both i.v. and oral administration, a finding that was confirmed by plasma metabolite profiling. Metabolite profiling and specific/selective LC-MS assays identified and quantified two glucuronides of GSK1322322 (M6 and M9) in circulation. Metabolite M9 circulated at a level slightly exceeding 10% of total circulating compound-related materials, suggesting a need for further safety testing (ICH M3(R2), 2009). However, M9 had a short half-life (2.4 hours) and was unlikely to accumulate to a higher exposure level. The other glucuronide (M6) was circulating only at minute quantities (1% total plasma radioactivity). Neither glucuronide metabolite has been shown to have antibiotic activity (unpublished data).
After a single dose of GSK1322322 in healthy male subjects, the radioactivity excretion patterns were almost identical with i.v. and oral administration, with radioactivity approximately evenly split between urine and feces. This similarity in excretion patterns between the two routes was expected because GSK1322322 was almost completely absorbed and bioavailable after the oral dose. These patterns highlighted the equal importance of both biliary and renal elimination in GSK1322322 clearance and the potential effect of impairment of the liver and/or kidney on GSK1322322 disposition.
GSK1322322 was largely eliminated unchanged in the urine (30% of dose). The potential interaction of GSK1322322 with drugs that rely highly on renal elimination by transporters is possible and may be investigated in future studies.
Since glucuronidation was a predominant pathway in the preclinical species (unpublished data), it was predicted to be predominant in humans as well. Indeed, Entero-Test-collected bile sample analysis confirmed that the glucuronide of GSK1322322 (M9) was the major biliary radiocomponent in humans. Although the Entero-Test, a noninvasive and easy-to-use device, has been used in human bile collections before (Vonk et al., 1986; Muraca et al., 1989; Bloomer et al., 2012) , this is the first study, to our knowledge, that it has been successfully incorporated into a conventional human radiolabel study. Biliary metabolites have often been crucial in evaluating drug disposition, especially if the metabolites were unstable after biliary secretion into the gut. Historically, in human radiolabel studies, bile was frequently collected by duodenal intubation, followed by suction or aspiration (Balani et al., 1997; Wang et al., 2006) . These methods are complicated and invasive. The Entero-Test, on the other hand, is much less invasive, cheaper, and simpler method to obtain this data. In the present study, no subjects withdrew or suffered any adverse events related to this device. Bile was successfully collected from all five subjects in both i.v. and oral crossover sampling occasions. In addition, a food cue was all that was needed to induce sufficient bile flow in this study, unlike in other reported studies that involved i.v. administration of cholecystokinin to stimulate gallbladder contraction (Balani et al., 1997; Wang et al., 2006) . The successful implementation of Entero-Test in this study enabled an accurate assessment of GSK1322322 disposition in humans. Assuming the Entero-Test snapshot represented the full biliary excretion (% of dose in bile should be equivalent to the dose eliminated in feces resulting from almost complete absorption of GSK1322322), glucuronidation alone could account for metabolism of up to 30% of the administered dose in humans (25% in bile and 5% in urine after oral administration). We have not investigated the enzymes responsible for the glucuronidation pathway. However, uridine 59-diphosphoglucuronosyltransferases in general are high-capacity enzymes with low substrate specificity. Uridine 59-diphosphoglucuronosyltransferase inhibition has rarely resulted in significant clinical drug interactions (Williams et al., 2004) .
Biliary glucuronides of GSK1322322 were not stable once they entered the gastrointestinal tract, as evidenced by the observed low levels of these metabolites in the feces in comparison with the bile samples. Without the Entero-Test, the contribution of glucuronidation to GSK1322322 metabolism would have been notably underestimated. These glucuronides were likely hydrolyzed back to the aglycones by the microbes in the large intestine. Glycoside/glucuronide hydrolysis is a common metabolic pathway by gut microbes (Sousa et al., 2008 ). The resulting aglycone could then be reabsorbed and complete the cycle of enterohepatic recirculation. Although not evident in this study, enterohepatic recirculation might be responsible for the appearance of a second peak at 4 hours postdose in the GSK1322322 plasma concentration-time profiles in a phase 1 study with GSK1322322 (Naderer et al., 2013B) .
Human feces contained high levels of an N-dehydroxylated product of GSK1322322 (M37). N-dehydroxylation has been observed in xenobiotic metabolism, including reduction of N-hydroxyformamide, the same moiety as in GSK1322322 (Sugihara et al., 2000; Stokvis et al., 2004) . The mechanism of this reduction has been extensively studied. Cytochrome b5 and its reductase and several molybdenumcontaining enzymes such as aldehyde oxidase were all capable of carrying out the reduction (Vonk et al., 1986; Saulter et al., 2005; Havemeyer et al., 2010) . Sugihara et al. (2000) also reported nonenzymatic N-dehydroxylation by hemoglobin under anaerobic conditions. In this study, we have demonstrated that gut microbes likely dehydroxylated GSK1322322. Gut microbes contained high levels of reductases (Sousa et al., 2008) . Weisburger et al. (1970) demonstrated gut microbial N-dehydroxylation of a carcinogen (N-hydroxy-N-2-fluorenylacetamide). Although GSK1322322 had antibacterial activity, it was only active against selected bacterial strains (Naderer et al., 2013A) . We speculated that the N-hydroxyformamide moiety of GSK1322322 and its nonglucuronidated metabolites (e.g., M1-M4), derived from biliary secretion or after microbial degradation, were susceptible to this gut microbial reduction. Boiling fecal contents, followed by treatment with broad-spectrum antibiotics, prevented the reduction of GSK1322322 in vitro. The reduced product was devoid of antibiotic activity (unpublished data). However, human reductase-catalyzed and/or nonenzymatic formation of M37 via hemoglobin-assisted reduction could not be ruled out since the reduction product was also detected in human blood, urine, and bile, albeit at low concentrations.
In summary, we report the results of a human metabolism and excretion study with successful bile collection using Entero-Test on an experimental antibiotic, GSK1322322. GSK1322322 was quickly absorbed with near complete (97%) bioavailability after single oral administration of 1200 mg in solution. Unchanged parent predominated in circulation after oral or i.v. administration (1200 or 1000 mg). A glucuronide metabolite of GSK1322322 (M9) also circulated at levels slightly .10% of total plasma radioactivity. A notable portion of GSK1322322 was excreted unchanged, mainly in urine (30% of total dose). Glucuronidation was likely the major pathway in metabolism (up to 30% of dose), with products excreted mostly via the bile. Oxidation played a minor role (,20% of dose) in elimination. Comparison of the biliary and fecal profiles indicates that the glucuronides are likely labile to the gut lumen. Gut microbes were capable of reducing GSK1322322 before fecal elimination. 
Introduction
The major metabolites of GSK1322322 were structurally characterized using samples from rat isolated perfused rat liver and rat balance excretion studies using radiolabelled in vitro and in vivo studies. These studies are briefly described as follows.
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Materials and Methods
Isolated Perfused Rat Livers (IPRL)
To characterize the major metabolites of GSK1322322 in rat bile, an isolated perfused rat liver experiment was conducted. Three male rats (Sprague-Dawley strain supplied by Charles River Laboratories, Inc., Raleigh, NC) were used in this study. Animals were surgically cannulated and connected to the perfusion apparatus using an established procedure (Curtis et al., 1971) . The dose was delivered at a target dose of 30 mg/kg Post-dose bile was collected, and stored at -70°C if not in use. The biliary recovery of the total administered radioactivity was 61%, 31% and 62% from rat livers 1, 2 and 3, respectively. The weight of bile produced during the perfusion experiment by rats 1, 2 and 3 were ca 2.9, 1.7 and 2.3 g, respectively. All the bile samples were pooled to give a single representative sample of bile, vortex mixed and then centrifuged at ca 12,000 g av (Eppendorf 5415C, Brinkman Instruments, Westbury, NY) at ambient temperature for 5 minutes. The resulting supernatant was injected onto a semi-preparative column for isolation of M6 and M9. NMR analysis was used to determine their definite structures. The semipreparative HPLC and NMR conditions for the separation and analysis are detailed in Table   1 and Table 2 During these analyses, radio detection was used in parallel with the mass spectrometer to assist the identification of radio-labeled drug related materials and to confirm peak assignments. The HPLC and the mass spectrometric conditions used for analyzing the samples are detailed in Table 3 .
Results
As summarized in Table 4 (of Supplemental Data), M6 and M9 were structurally characterized by NMR and LC-MS n analysis in these two studies, with the accurate mass data obtained during the in vivo rat study. Metabolites M1 to M4 were also characterized using accurate mass HPLC-MS n .
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